These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 2976952)

  • 21. A comparative study of systemic subantimicrobial and topical treatment of minocycline in experimental periodontitis of rats.
    Xu Y; Wei W
    Arch Oral Biol; 2006 Sep; 51(9):794-803. PubMed ID: 16712777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of biochemical markers of bone turnover in rats after clodronate administration.
    Díaz Diego EM; de la Piedra C
    Miner Electrolyte Metab; 1993; 19(6):368-72. PubMed ID: 8164618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of diphosphonate on inflammatory-resorptive horizontal bone destruction--an animal model].
    Seichter U
    Dtsch Zahnarztl Z; 1983 Oct; 38(10):921-4. PubMed ID: 6580135
    [No Abstract]   [Full Text] [Related]  

  • 24. Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat.
    Jung A; Bornand J; Mermillod B; Edouard C; Meunier PJ
    Cancer Res; 1984 Jul; 44(7):3007-11. PubMed ID: 6233002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of disodium ethane-hydroxy-1,1-diphosphonate and disodium dichloromethylene diphosphonate on lanthanide-induced calcergy.
    McClure J
    J Pathol; 1982 Jun; 137(2):159-65. PubMed ID: 6211530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
    Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic bone disease: role of bisphosphonates.
    McKenna MJ; Freaney R; Crown J
    Ir Med J; 1995; 88(6):189. PubMed ID: 8575911
    [No Abstract]   [Full Text] [Related]  

  • 28. [Diphosphonates and primary hyperparathyroidism].
    Conte N; Breda F; Di Virgilio R; Legovini P; Roiter I; Foscolo G; Caenaro G
    Ann Ital Med Int; 1988; 3(4):278-82. PubMed ID: 2978945
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathological fracture of the mandible treated with diphosphonates.
    Califano L; Zupi A; Maremonti P
    Br J Oral Maxillofac Surg; 1998 Aug; 36(4):319. PubMed ID: 9762465
    [No Abstract]   [Full Text] [Related]  

  • 30. [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Chatani Y
    Clin Calcium; 2005 Jan; 15(1):9-14. PubMed ID: 15632466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic, histomorphometric, and densitometric analyses.
    Barou O; Lafage-Proust MH; Martel C; Thomas T; Tirode F; Laroche N; Barbier A; Alexandre C; Vico L
    J Pharmacol Exp Ther; 1999 Oct; 291(1):321-8. PubMed ID: 10490920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Knowledge of the truth in terminal patients].
    Sanz Ortiz J
    Med Clin (Barc); 1988 Apr; 90(13):538-9. PubMed ID: 2969066
    [No Abstract]   [Full Text] [Related]  

  • 33. The beneficial effects of diphosphonate and piroxicam on the osteolytic and metastatic spread of rat prostate carcinoma cells.
    Pollard M; Luckert PH
    Prostate; 1986; 8(1):81-6. PubMed ID: 2935791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological topics of bone metabolism: a novel bisphosphonate for the treatment of periodontitis.
    Shinoda H; Takeyama S; Suzuki K; Murakami S; Yamada S
    J Pharmacol Sci; 2008 Apr; 106(4):555-8. PubMed ID: 18431039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inhibitory effects of bisphosphonates on the resorption of alveolar bone in rats].
    Kobayashi M
    Nihon Shishubyo Gakkai Kaishi; 1985 Mar; 27(1):51-64. PubMed ID: 3161960
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mechanism of action of bisphosphonate].
    Udagawa N; Takahashi N
    Nihon Rinsho; 2003 Feb; 61(2):178-81. PubMed ID: 12638205
    [No Abstract]   [Full Text] [Related]  

  • 37. CMT-8/clodronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis.
    Llavaneras A; Golub LM; Rifkin BR; Heikkilä P; Sorsa T; Teronen O; Salo T; Liu Y; Ryan ME; Ramamurthy NS
    Ann N Y Acad Sci; 1999 Jun; 878():671-4. PubMed ID: 10415804
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel bone antiresorptive approaches.
    Lark MW; James IE
    Curr Opin Pharmacol; 2002 Jun; 2(3):330-7. PubMed ID: 12020479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic modulation of clodronate in local therapy of periodontal and implant inflammation.
    Volpi R; Rossi F; Trisi P; Testori T; Berardi D; Perfetti G
    Int J Immunopathol Pharmacol; 2007; 20(1 Suppl 1):69-74. PubMed ID: 17897505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Plosker GL; Goa KL
    Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.